Inactive Instrument

Abpro Corporation

US0008501076

Abpro Corporation announced that it has received $12.39 million in funding

March 23, 2016

On March 24, 2016, Abpro Corporation closed the transaction. The company has received $12,389,994 in funding from seven investors.

Latest news about Abpro Corporation

Abpro Corporation entered into a term sheet to acquire Atlantic Coastal Acquisition Corp. II from a group of shareholders for approximately $770 million in a reverse merger transaction.	20/09/23	CI
Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of Cancer Treatment Bispecific Antibody	21/09/22	CI
Abpro Corporation announced that it expects to receive $79.999992 million in funding	29/03/22	CI
Abpro Corporation Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant	09/12/21	CI
Abpro Announces Positive Phase 1 Results Demonstrating a Favorable Safety and Pharmacokinetic Profile of ABP 300, a Neutralizing Antibody Therapeutic for the Treatment of COVID-19	02/02/21	CI
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19	16/12/20	CI
Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19	20/10/20	CI
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets	03/03/20	CI
Abpro Corporation announced that it expects to receive $29.999984 million in funding from Abpro Bio International, Inc.	30/10/19	CI
Abpro and NJCTTQ Enters Into Partnership for Development of Multiple Novel Bispecific Antibodies	28/02/19	CI
Abpro Corporation has withdrawn its IPO in the amount of $64 million.	16/05/18	CI
Abpro Corporation has filed an IPO in the amount of $69 million.	11/04/18	CI
Abpro Seeks Acquisitions	11/04/18	CI
Abpro Corporation announced that it has received $9.99999 million in funding	06/04/17	CI
Abpro Corporation announced a financing transaction	30/03/17	CI
Abpro Appoints MacBeath as Chief Scientific Officer	21/03/17	CI
Abpro Announces Agreements with Massachusetts General Hospital and Brigham and Women's Hospital to Co-Develop Therapeutics for Inflammation, Autoimmunity, Fibrosis, Oncology	19/05/16	CI
Abpro Announces Investment and Partnership with Essex Bio for Development of Antibody Therapeutics	06/04/16	CI
Abpro Corporation announced that it has received $3.5 million in funding from Essex Bio-Technology Limited	05/04/16	CI
Abpro Corporation announced that it has received $12.39 million in funding	23/03/16	CI
Abpro Corporation announced that it expects to receive $20 million in funding	10/03/16	CI
Abpro Corporation announced that it expects to receive $3.5 million in funding from Essex Bio-Technology Limited	21/01/16	CI

Abpro Corporation, incorporated on August 18, 2004, is a biotechnology company that is engaged in developing antibody therapeutics. The Company is focused on antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. With the Company's Divers Immune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. The Company? s DiversImmune and MultiMab platforms and licensing strategy has generated a wide range pipeline of antibody product candidates, that includes ABP-100, ABP-110, ABP-130, ABP-300, ABP-500, ABP-201, ABP-200, and ABP-400. The Company's lead candidate, ABP-100, is a immuno-oncology TetraBi antibody that targets human epidermal growth factor receptor 2 (HER2) and cluster of differentiation 3 (CD3) for the treatment of HER2+ solid tumors, including breast, gastric, and endometrial cancers.

Sector

More about the company